Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab
2019 ASCO Annual MeetingDanny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase III results that support pembrolizumab with and without platinum-based chemotherapy plus fluorouracil as new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma (Abstract 6000).
Related Videos
Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy
Alok A. Khorana, MD, of the Cleveland Clinic, and Hedy L. Kindler, MD, of The University of Chicago, discuss phase III findings on olaparib as maintenance treatment following first...
Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Breast Cancer: Next Steps in Immunotherapy
Hope S. Rugo, MD, of the University of California, San Francisco, and Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discuss on...
Kim N. Chi, MD, on Metastatic Castration-Sensitive Prostate Cancer: First Results From the TITAN Trial
Kim N. Chi, MD, of BC Cancer, discusses the first phase III findings from the TITAN study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate ...
Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine
Adam Brufsky, MD, PhD, of Magee-Womens Hospital and the Hillman Cancer Center at the University of Pittsburgh Medical Center, discusses phase III study findings on neratinib ...
Sara A. Hurvitz, MD, on HR+/HER2− Advanced Breast Cancer: MONALEESA-7 Trial on Endocrine Therapy With or Without Ribociclib
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses the first study of ribociclib plus endocrine therapy vs endocrine therapy alone to demonstrate...
